RT Journal Article
SR Electronic
T1 Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.19.20214494
DO 10.1101/2020.10.19.20214494
A1 Carole H. Sudre
A1 Benjamin Murray
A1 Thomas Varsavsky
A1 Mark S. Graham
A1 Rose S. Penfold
A1 Ruth C. Bowyer
A1 Joan Capdevila Pujol
A1 Kerstin Klaser
A1 Michela Antonelli
A1 Liane S. Canas
A1 Erika Molteni
A1 Marc Modat
A1 M. Jorge Cardoso
A1 Anna May
A1 Sajaysurya Ganesh
A1 Richard Davies
A1 Long H Nguyen
A1 David A. Drew
A1 Christina M. Astley
A1 Amit D. Joshi
A1 Jordi Merino
A1 Neli Tsereteli
A1 Tove Fall
A1 Maria F. Gomez
A1 Emma L. Duncan
A1 Cristina Menni
A1 Frances M.K. Williams
A1 Paul W. Franks
A1 Andrew T. Chan
A1 Jonathan Wolf
A1 Sebastien Ourselin
A1 Tim Spector
A1 Claire J. Steves
YR 2020
UL http://medrxiv.org/content/early/2020/12/19/2020.10.19.20214494.abstract
AB Reports of “Long-COVID”, are rising but little is known about prevalence, risk factors, or whether it is possible to predict a protracted course early in the disease. We analysed data from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID Symptom Study app. 558 (13.3%) had symptoms lasting >=28 days, 189 (4.5%) for >=8 weeks and 95 (2.3%) for >=12 weeks. Long-COVID was characterised by symptoms of fatigue, headache, dyspnoea and anosmia and was more likely with increasing age, BMI and female sex. Experiencing more than five symptoms during the first week of illness was associated with Long-COVID, OR=3.53 [2.76;4.50]. A simple model to distinguish between short and long-COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample of 2472 antibody positive individuals. This model could be used to identify individuals for clinical trials to reduce long-term symptoms and target education and rehabilitation services.Competing Interest StatementZoe Global Limited co-developed the app pro bono for non-commercial purposes. Investigators received support from the Wellcome Trust, the MRC/BHF, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. RD, JW, JCP, SG and AM work for Zoe Global Limited and TDS and PWF are consultants to Zoe Global Limited. LHN, DAD, PWF and ATC previously participated as investigators on a diet study unrelated to this work that was supported by Zoe Global Ltd.Funding StatementZoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare. Investigators also received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work through a Stuart and Suzanne Steele MGH Research Scholar Award. CM is funded by the Chronic Disease Research Foundation and by the MRC AimHy project grant. LHN, DAD, ADJ, ADS, CG, WL are supported by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz. The work performed on the Swedish study is supported by grants from the Swedish Research Council, Swedish Heart-Lung Foundation and the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In the UK, the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all subscribers provided consent. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020-01803).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study is available to bona fide researchers through UK Health Data Research using the following link https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259